paclitaxel has been researched along with bq 123 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagnato, A; Biroccio, A; Del Bufalo, D; Di Castro, V; Rosanò, L; Salani, D; Spinella, F | 1 |
| Hu, Y; Jiang, T; Jiang, X; Jin, K; Liu, X; Luo, Z; Pang, Z; Shen, S; Tuo, Y; Wang, H; Zhang, B | 1 |
2 other study(ies) available for paclitaxel and bq 123
| Article | Year |
|---|---|
Endothelin-1 acts as a survival factor in ovarian carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Survival; Endothelin Receptor Antagonists; Endothelin-1; Female; Humans; Oligopeptides; Ovarian Neoplasms; Paclitaxel; Peptides, Cyclic; Piperidines; Receptor, Endothelin A; Receptor, Endothelin B; Tumor Cells, Cultured | 2002 |
BQ123 selectively improved tumor perfusion and enhanced nanomedicine delivery for glioblastomas treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Delivery Systems; Endothelin Receptor Antagonists; Glioblastoma; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Peptides, Cyclic | 2018 |